Inventor · disambiguated record
Arumugam Muruganandam
Also filed as: MURUGANANDAM ARUMUGAM
10 granted patents·18 pending applications·249 citations·filing 2001–2024
92Inventor score
Files withDYAX CORP8MERRIMACK PHARMACEUTICALS INC5SCHOEBERL BIRGIT3ABULROB ABEDELNASSER2CA NAT RESEARCH COUNCIL2
Top patents by PatentIndex Score
28 records- 0198US7846440B2Antibodies against ErbB3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2008·Granted Dec 7, 2010·92 cites·18 claims
- 0295US9260520B2Antibodies to FeRn and uses thereofDYAX CORP·Filed 2014·Granted Feb 16, 2016·18 cites·6 claims
- 0394US8961966B2Antibodies against ERBB3 and uses thereofSCHOEBERL BIRGIT·Filed 2010·Granted Feb 24, 2015·20 cites·15 claims
- 0494US8815246B2Fc receptor binding proteinsTENHOOR CHRISTOPHER·Filed 2012·Granted Aug 26, 2014·18 cites·12 claims
- 0594US8691225B2Antibodies against the ectodomain of ErbB3 and uses thereofSCHOEBERL BIRGIT·Filed 2009·Granted Apr 8, 2014·26 cites·20 claims
- 0694US8273351B2Fc receptor binding proteinsTENHOOR CHRISTOPHER·Filed 2009·Granted Sep 25, 2012·20 cites·6 claims
- 0792US8383107B2Single domain brain-targeting antibody fragments derived from llama antibodiesCA NAT RESEARCH COUNCIL·Filed 2011·Granted Feb 26, 2013·9 cites·22 claims
- 0890US7943129B2Single-domain brain-targeting antibody fragments derived from llama antibodiesCA NAT RESEARCH COUNCIL·Filed 2001·Granted May 17, 2011·32 cites·12 claims
- 0990US2024360243A1Antibodies against the ectodomain of erbb3 and uses thereofELEVATION ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 1088US8715659B2Single domain brain-targeting antibody fragments derived from llama antibodiesNAT RESEARH COUNCIL OF CANADA·Filed 2013·Granted May 6, 2014·10 cites·18 claims
- 1185US9487588B2Antibodies against the ectodomain of ERBB3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Nov 8, 2016·4 cites·4 claims
- 1279US2022204642A1Antibodies against the ectodomain of erbb3 and uses thereofELEVATION ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 1369US2010056761A1Antibodies against erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 1469US2019292271A1Antibodies against the ectodomain of erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1565US2016222110A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 1665US2013045218A1Fc receptor binding proteinsSYNTONIX PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 1763US2016194397A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 1863US2009162422A1Single-domain brain-targeting antibody fragments derived from LLAMA antibodiesNAT RES COUNCIL ACT BY THE PAR·Filed 2007·Application pending·0 cites
- 1963US2016222111A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 2063US2016222112A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 2163US2016222109A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 2263US2016222108A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 2363US2017073427A1Antibodies against the ectodomain of erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2457US2015238637A1Blood-brain Barrier Epitopes and Uses ThereofNAT RES COUNCIL CANADA·Filed 2015·Application pending·0 cites
- 2552US2011097739A1Blood-brain barrier epitopes and uses thereofABULROB ABEDELNASSER·Filed 2010·Application pending·0 cites
- 2652US2009275124A1Methods and Compositions Comprising Anti-Idiotypic Antibodies to Anti-MMP-14 AntibodiesDYAX CORP·Filed 2009·Application pending·0 cites
- 2751US2009047300A1Blood-brain barrier epitopes and uses thereofABULROB ABEDELNASSER·Filed 2006·Application pending·0 cites
- 2850US2012244163A1Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereofSCHOEBERL BIRGIT·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Arumugam Muruganandam files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →